27755168|t|Mesenchymal stromal cells in clinical kidney transplantation: how tolerant can it be?
27755168|a|Progress in the improvement of short-term and long-term outcomes of kidney transplantation seems to have reached a plateau, partially due to consequences of very efficient, but nonspecific immunosuppressive drugs. In recent years, various forms of cell therapy, including the use of mesenchymal stromal cells, have been put forward as an alternative strategy for more defined therapy. It is thought that these therapies will not only allow controlled tapering of immunosuppressive medication, but might bring us also closer to the ambition of generating donor -specific immune regulation and tolerance. Different forms of alloimmunity, including direct, indirect and semi-direct alloantigen presentation have to be controlled before donor -specific immune regulation can be reached. Several mechanisms have been described how mesenchymal stromal cells can affect alloimmunity. Especially, the interaction with professional antigen presenting cells, like dendritic cells, is of critical importance. This review will discuss the current status of ongoing clinical trials with mesenchymal stromal cells in kidney transplantation and specifically concentrate on the possibilities and impossibilities of how these therapeutic strategies can contribute to control of the different forms of alloreactivity operation in organ transplantation.
27755168	0	25	Mesenchymal stromal cells	T025	C3178844
27755168	29	37	clinical	T080	C0205210
27755168	38	60	kidney transplantation	T061	C0022671
27755168	66	74	tolerant	T169	C0231198
27755168	86	94	Progress	T169	C1280477
27755168	102	113	improvement	T077	C2986411
27755168	117	127	short-term	T079	C0443303
27755168	132	141	long-term	T079	C0443252
27755168	142	150	outcomes	T080	C0085415
27755168	154	176	kidney transplantation	T061	C0022671
27755168	201	208	plateau	T081	C2964353
27755168	227	242	consequences of	T169	C0686907
27755168	248	257	efficient	T080	C0442799
27755168	263	274	nonspecific	T078	C0750540
27755168	275	298	immunosuppressive drugs	T121,T129	C0021081
27755168	334	346	cell therapy	T061	C0302189
27755168	369	394	mesenchymal stromal cells	T025	C3178844
27755168	424	435	alternative	T077	C1523987
27755168	436	444	strategy	T170	C0679716
27755168	462	469	therapy	T061	C0087111
27755168	496	505	therapies	T061	C0087111
27755168	526	536	controlled	T169	C2587213
27755168	537	545	tapering	T058	C0441640
27755168	549	577	immunosuppressive medication	T121,T129	C0021081
27755168	617	625	ambition	T041	C0870128
27755168	629	639	generating	T052	C3146294
27755168	640	645	donor	T098	C0013018
27755168	656	673	immune regulation	T040	C1327458
27755168	678	687	tolerance	T046	C0020963
27755168	708	720	alloimmunity	T042	C0598604
27755168	732	738	direct	T080	C0439851
27755168	740	748	indirect	T080	C0439852
27755168	753	764	semi-direct	T080	C0205556
27755168	765	776	alloantigen	T129	C0002131
27755168	819	824	donor	T098	C0013018
27755168	835	852	immune regulation	T040	C1327458
27755168	877	887	mechanisms	T169	C0441712
27755168	912	937	mesenchymal stromal cells	T025	C3178844
27755168	949	961	alloimmunity	T042	C0598604
27755168	979	990	interaction	T043	C0007582
27755168	1009	1033	antigen presenting cells	T025	C0003315
27755168	1040	1055	dendritic cells	T025	C0011306
27755168	1063	1071	critical	T080	C1511545
27755168	1072	1082	importance	T080	C3898777
27755168	1113	1120	current	T079	C0521116
27755168	1121	1127	status	T080	C0449438
27755168	1139	1154	clinical trials	T062	C0008976
27755168	1160	1185	mesenchymal stromal cells	T025	C3178844
27755168	1189	1211	kidney transplantation	T061	C0022671
27755168	1295	1317	therapeutic strategies	T061	C0087111
27755168	1322	1332	contribute	T052	C1880177
27755168	1336	1343	control	T080	C0243148
27755168	1370	1384	alloreactivity	T042	C0598604
27755168	1398	1419	organ transplantation	T061	C0029216